These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 34876151)

  • 21. A retrospective analysis of weight changes in HIV-positive patients switching from a tenofovir disoproxil fumarate (TDF)- to a tenofovir alafenamide fumarate (TAF)-containing treatment regimen in one German university hospital in 2015-2017.
    Gomez M; Seybold U; Roider J; Härter G; Bogner JR
    Infection; 2019 Feb; 47(1):95-102. PubMed ID: 30269210
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Weight gain before and after switch from TDF to TAF in a U.S. cohort study.
    Mallon PW; Brunet L; Hsu RK; Fusco JS; Mounzer KC; Prajapati G; Beyer AP; Wohlfeiler MB; Fusco GP
    J Int AIDS Soc; 2021 Apr; 24(4):e25702. PubMed ID: 33838004
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tenofovir alafenamide for hepatitis B virus infection including switching therapy from tenofovir disoproxil fumarate.
    Kaneko S; Kurosaki M; Tamaki N; Itakura J; Hayashi T; Kirino S; Osawa L; Watakabe K; Okada M; Wang W; Shimizu T; Higuchi M; Takaura K; Yasui Y; Tsuchiya K; Nakanishi H; Takahashi Y; Watanabe M; Izumi N
    J Gastroenterol Hepatol; 2019 Nov; 34(11):2004-2010. PubMed ID: 31017689
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety of Tenofovir Alafenamide in People With HIV Who Experienced Proximal Renal Tubulopathy on Tenofovir Disoproxil Fumarate.
    Campbell L; Barbini B; Burling K; Cromarty B; Hamzah L; Johnson M; Jones R; Samarawickrama A; Williams D; Winston A; Post FA;
    J Acquir Immune Defic Syndr; 2021 Oct; 88(2):214-219. PubMed ID: 34506361
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Changes in Glomerular Filtration Rate After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide Fumarate for Human Immunodeficiency Virus Preexposure Prophylaxis.
    Rivera AS; Pak K; Mefford MT; Hechter RC
    Open Forum Infect Dis; 2024 Feb; 11(2):ofad695. PubMed ID: 38352151
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Changes in renal and metabolic indices after switching from tenofovir disoproxil fumarate- to tenofovir alafenamide-containing ART among individuals with HIV in Canada: A retrospective study.
    Shokoohi M; Gupta M; Crouzat F; Smith G; Kovacs C; Brunetta J; Chang B; Knox D; Acsai M; Merkley B; Giolma K; Fletcher D; Loutfy M
    Int J STD AIDS; 2021 Aug; 32(9):861-871. PubMed ID: 33890817
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effectiveness and Renal Safety of Tenofovir Alafenamide Fumarate among Chronic Hepatitis B Patients: Real-World Study.
    Farag MS; Fung S; Tam E; Doucette K; Wong A; Ramji A; Conway B; Cooper C; Tsoi K; Wong P; Sebastiani G; Brahmania M; Haylock-Jacobs S; Coffin CS; Hansen BE; Janssen HLA
    J Viral Hepat; 2021 Jun; 28(6):942-950. PubMed ID: 33749086
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Improved bone and renal safety in younger tenofovir disoproxil fumarate experienced chronic hepatitis B patients after switching to tenofovir alafenamide or entecavir.
    Da Wang F; Zhou J; Li LQ; Li YJ; Wang ML; Tao YC; Zhang DM; Wang YH; Chen EQ
    Ann Hepatol; 2023; 28(5):101119. PubMed ID: 37271480
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of the regimens containing tenofovir alafenamide versus tenofovir disoproxil fumarate in fixed-dose single-tablet regimens for initial treatment of HIV-1 infection: A meta-analysis of randomized controlled trials.
    Tao X; Lu Y; Zhou Y; Zhang L; Chen Y
    Int J Infect Dis; 2020 Apr; 93():108-117. PubMed ID: 31988012
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Metabolic-Related Outcomes After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in Adults With Human Immunodeficiency Virus (HIV): A Multicenter Prospective Cohort Study.
    Martínez-Sanz J; Serrano-Villar S; Muriel A; García Fraile LJ; Orviz E; Mena de Cea Á; Campins AA; Moreno S
    Clin Infect Dis; 2023 Feb; 76(3):e652-e660. PubMed ID: 35903910
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Switching to coformulated rilpivirine (RPV), emtricitabine (FTC) and tenofovir alafenamide from either RPV, FTC and tenofovir disoproxil fumarate (TDF) or efavirenz, FTC and TDF: 96-week results from two randomized clinical trials.
    Hagins D; Orkin C; Daar ES; Mills A; Brinson C; DeJesus E; Post FA; Morales-Ramirez J; Thompson M; Osiyemi O; Rashbaum B; Stellbrink HJ; Martorell C; Liu H; Liu YP; Porter D; Collins SE; SenGupta D; Das M
    HIV Med; 2018 Nov; 19(10):724-733. PubMed ID: 30101539
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment with tenofovir alafenamide fumarate worsens the lipid profile of HIV-infected patients versus treatment with tenofovir disoproxil fumarate, each coformulated with elvitegravir, cobicistat, and emtricitabine.
    Cid-Silva P; Fernández-Bargiela N; Margusino-Framiñán L; Balboa-Barreiro V; Mena-De-Cea Á; López-Calvo S; Vázquez-Rodríguez P; Martín-Herranz I; Míguez-Rey E; Poveda E; Castro-Iglesias Á
    Basic Clin Pharmacol Toxicol; 2019 Apr; 124(4):479-490. PubMed ID: 30388308
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tenofovir Alafenamide for Drug-Resistant Hepatitis B: A Randomized Trial for Switching From Tenofovir Disoproxil Fumarate.
    Byun KS; Choi J; Kim JH; Lee YS; Lee HC; Kim YJ; Yoo BC; Kwon SY; Gwak GY; Lim YS
    Clin Gastroenterol Hepatol; 2022 Feb; 20(2):427-437.e5. PubMed ID: 33962041
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tenofovir Alafenamide Fumarate Therapy for HIV Treatment: Cardiometabolic and Renal Safety.
    Petrakis V; Panagopoulos P; Papachristou S; Papanas N; Terzi I; Trypsianis G; Papazoglou D
    AIDS Res Hum Retroviruses; 2020 Sep; 36(9):697-702. PubMed ID: 32527142
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of switch from tenofovir disoproxil fumarate-based regimens to tenofovir alafenamide-based regimens on lipid profile, weight gain and cardiovascular risk score in people living with HIV.
    Plum PE; Maes N; Sauvage AS; Frippiat F; Meuris C; Uurlings F; Lecomte M; Léonard P; Paquot N; Fombellida K; Vaira D; Moutschen M; Darcis G
    BMC Infect Dis; 2021 Sep; 21(1):910. PubMed ID: 34488664
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Weight changes in patients with sustained viral suppression switching tenofovir disoproxil fumarate to tenofovir alafenamide.
    Schafer JJ; Zimmerman M; Walshe C; Cerankowski J; Shimada A; Keith SW
    Obesity (Silver Spring); 2022 Jun; 30(6):1197-1204. PubMed ID: 35674696
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Plasma concentration of neurofilament light chain protein decreases after switching from tenofovir disoproxil fumarate to tenofovir alafenamide fumarate.
    Hermansson L; Yilmaz A; Price RW; Nilsson S; McCallister S; Makadzange T; Das M; Zetterberg H; Blennow K; Gisslen M
    PLoS One; 2019; 14(12):e0226276. PubMed ID: 31826005
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Switch from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in People Living with HIV: Lipid Changes and Statin Underutilization.
    Brunet L; Mallon P; Fusco JS; Wohlfeiler MB; Prajapati G; Beyer A; Fusco GP
    Clin Drug Investig; 2021 Nov; 41(11):955-965. PubMed ID: 34546533
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate in the First Protease Inhibitor-Based Single-Tablet Regimen for Initial HIV-1 Therapy: A Randomized Phase 2 Study.
    Mills A; Crofoot G; McDonald C; Shalit P; Flamm JA; Gathe J; Scribner A; Shamblaw D; Saag M; Cao H; Martin H; Das M; Thomas A; Liu HC; Yan M; Callebaut C; Custodio J; Cheng A; McCallister S
    J Acquir Immune Defic Syndr; 2015 Aug; 69(4):439-45. PubMed ID: 25867913
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and Renal Safety of Prophylactic Tenofovir Alafenamide for HBV-Infected Cancer Patients Undergoing Chemotherapy.
    Lee IC; Lan KH; Su CW; Li CP; Chao Y; Lin HC; Hou MC; Huang YH
    Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232631
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.